The evidence levels and strength of recommendation for more extended measurmenet of Lp(a) will depend on clinical outcome trials employing specific therapies (such as apo(a) ASOs and siRNAs) targeted at high-risk patients (e.g., ASCVD, FH, or diabetes) with elevated Lp(a). The gene discussed is LPA; the disease is diabetes mellitus.